Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Amivantamab Plus Chemotherapy Nearly Doubles PFS in EGFR Exon 20–Mutant NSCLC

October 21st 2023

The combination of amivantamab-vmjw (Rybrevant) and chemotherapy produced a median progression-free survival of 11.4 months vs 6.7 months with chemotherapy alone in patients with advanced, EGFR exon 20 insertion–positive non–small cell lung cancer.

Alectinib Elicits DFS Benefit in Early-Stage, Resected, ALK+ NSCLC

October 21st 2023

Treatment with the oral ALK inhibitor alectinib led to a statistically significant improvement in disease-free survival in patients with resected ALK-positive non–small cell lung cancer.

Perioperative Nivolumab Significantly Improves EFS in Previously Untreated Resectable NSCLC

October 21st 2023

Neoadjuvant treatment with nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab resulted in a statistically significant improvement in event-free survival vs placebo plus chemotherapy, in patients with previously untreated resectable stage II to IIIB non-small cell lung cancer, according to data from the phase 3 CheckMate 77T trial.

Selpercatinib Significantly Improves PFS Vs Chemo With or Without Pembrolizumab in RET+ NSCLC

October 21st 2023

Selpercatinib (Retevmo) showcased superior efficacy, with improved progression-free survival, vs chemotherapy with or without pembrolizumab in the first-line treatment of patients with RET fusion–positive non–small cell lung cancer.

Second-Line Sacituzumab Govitecan Elicits Responses, Provides Disease Control in ES-SCLC

October 21st 2023

Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

Dostarlimab Plus Chemo Continues to Demonstrate Strong Clinical Efficacy in Advanced NSCLC

October 20th 2023

Dostarlimab plus chemotherapy elicited a higher objective response rate and showcased a numerical improvement in overall survival compared with pembrolizumab and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Pembrolizumab Plus Adagrasib Demonstrates Preliminary Efficacy in KRAS G12C–Mutated NSCLC

October 20th 2023

Concurrent adagrasib and pembrolizumab generated early signals of efficacy in patients with treatment-naïve, advanced non–small cell lung cancer harboring KRAS G12C mutations, particularly in those who had a PD-L1 tumor proportion score of at least 50%.

Tarlatamab Demonstrates Antitumor Activity With Durable Responses in Previously Treated SCLC

October 20th 2023

Treatment with the bispecific T-cell engager tarlatamab demonstrated antitumor activity and favorable safety outcomes in patients with previously treated small cell lung cancer.

Toxicity Management for T-DM1 and T-DXd in Breast Cancer

October 20th 2023

Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].

Antibody-Drug Conjugates in Breast Cancer

October 20th 2023

A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.

ESMO 2023: Experts Preview Anticipated Data Spanning Tumor Types

October 19th 2023

The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies.

Novel KRAS G12C Inhibitor Reflects Research Advances in NSCLC and CRC

October 19th 2023

David S. Hong, MD, and David Sommerhalder, MD, discuss the unmet needs for patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) that prompted the initiation of the RMC-6291-001 trial; the key efficacy and safety findings with RMC-6291 in patients with NSCLC and CRC; and potential next steps for this agent.

Treatments and Unmet Needs for EGFR-Mutated NSCLC

October 19th 2023

Expert perspectives on unmet needs and therapies available for patients with EGFR-mutated non–small cell lung cancer.

EGFR-Mutated NSCLC: Treatment Options Following Progression on Osimertinib

October 19th 2023

Ticiana Leal, MD, gives a comprehensive overview of treatment options for patients with EGFR-mutated NSCLC who progress on osimertinib therapy.

Dr Iams on the Impact of Adagrasib on Patient Outcomes in KRAS G12C–Mutant NSCLC

October 18th 2023

Wade T. Iams, MD, discusses the impact of adagrasib on the treatment of patients with KRAS G12C-mutant NSCLC in the second line, as well as its integration into clinical practice.

Dr Hong on Preliminary Activity With RMC-6291 in Advanced KRAS G12C–Mutant Solid Tumors

October 18th 2023

David S. Hong, MD, discusses preliminary efficacy data from a phase 1 trial f the KRAS G12C inhibitor RMC-6291 in advanced KRAS G12C–mutant solid tumors.

DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC

October 18th 2023

Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.

FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable NSCLC

October 16th 2023

The FDA has approved pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment for patients with resectable non–small cell lung cancer.

Dr Abughanimeh on the Evolution of Targeted Therapy in EGFR+ NSCLC

October 16th 2023

Omar Abughanimeh, MD, discusses the evolution of targeted therapies for patients with EGFR-positive non-small cell lung cancer.

Dendritic Cell Vaccination Fails to Improve OS, Still Bolsters Immune Activation in Mesothelioma

October 16th 2023

Joachim G. J. V. Aerts, MD, PhD, discusses how dendritic cell vaccines could bolster historically poor responses to immunotherapy in patients with mesothelioma, reports and provides potential explanations for negative results from the DENIM trial, and details a potential role for this therapy in earlier lines of mesothelioma treatment.